Senior Director, Economic Modeling

Das ist der Job

The company’s RD pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins.

Darum lohnt es sich

As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. /p h3The Opportunity /h3 pSenior Director of Economic Modeling is responsible for defining and executing the economic modeling strategy to produce high quality health economic models and modeling strategies across the Rev Meds portfolio.

This is an exceptional opportunity to contribute to the advancement of healthcare by providing evidence that can shape the future of patient care in oncology. /p h3Key Strategic Responsibilities /h3 ul liLead the development of strategic and operational plans for health economic modeling within Global HEOR RWE (e.g., early and submission cost‑effectiveness/utility models, budget impact models, and country adaptations) while ensuring alignment with Integrated Evidence Plans and appropriate Global stakeholders. /li liPartner with Global HEOR RWE Executive Directors on core health economic modeling plans to support HTA, payer, and other access stakeholder assessments, submissions, negotiations, including associated value/HTA deliverables and publications to meet business and access objectives. /li liProvide strategic, methodological and analytical leadership to teams and countries for adaptation of economic models for local HTA submissions. /li liLead the development of an approach to monitor, educate and integrate evolving HTA guidelines, payer requirements, and methodologic advancements related to economic modeling. /li liLead the development of robust governance, compliance, and readiness for all economic modeling activities by adhering to processes, guidelines, and project management standards. /li liRepresent Rev Med in global external working groups regarding modeling standards and innovation (e.g., ISPOR Special Interest groups). /li /ul h3Key Operational Responsibilities /h3 ul liSupport design and development of economic models from start to finish for products across Rev Meds portfolio. /li liDirect statistical analyses of real‑world data and clinical trial data (in collaboration with biostatistics) to generate inputs including treatment effects, survival extrapolations, resource use, and health utility estimates. /li liDesign evidence synthesis, including network meta‑analysis (NMA), and matching adjusted indirect comparisons (MAIC) to inform comparative effectiveness. /li /ul h3Required Skills, Experience and Education /h3 ul liAdvanced degree (Masters or PhD) in health economics, econometrics, biostatistics, mathematics, engineering or related field (DrPH, PharmD). /li liMinimum of 15 years with a Masters (or 13+ years with a PhD/PharmD/DrPH) of relevant experience in economic modeling in the pharmaceutical, biotech, or consulting setting. /li liHands‑on experience in developing cost‑effectiveness, budget impact models as well as NMA/MAIC. /li liTrack record of high impact publications in economic modeling for global access decision‑makers. /li liExperience supporting HTA submissions and payer evidence generation. /li liStrong written and interpersonal communication skills, with an ability to present complex technical information clearly. /liliProven leadership and ability to influence others without direct reporting relationships. /li liComfortable working in a global team across time zones. /li /ul h3Preferred Skills /h3 ul liExperience in oncology economic modeling is highly desirable, especially related to gastrointestinal and thoracic malignancies. /li /ul /p ppRevolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS‑addicted cancers.

The company’s RAS(ON) inhibitors daraxonrasib (RMC‑6236), a RAS(ON) multi‑selective inhibitor; elironrasib (RMC‑6291), a RAS(ON) G12C‑selective inhibitor; zoldonrasib (RMC‑9805), a RAS(ON) G12D‑selective inhibitor; and RMC‑5127, a RAS(ON) G12V‑selective inhibitor, are currently in clinical development.